PTGS2 and colorectal carcinoma: Taken together, our data demonstrate the feasibility of an RNAi-based/InvColi-driven approach for COX-2 silencing aimed at the prevention of CRC or the treatment of other inflammatory bowel diseases characterised by COX-2 overexpression.